GB8813527D0 - Bispecific antibodies - Google Patents
Bispecific antibodiesInfo
- Publication number
- GB8813527D0 GB8813527D0 GB888813527A GB8813527A GB8813527D0 GB 8813527 D0 GB8813527 D0 GB 8813527D0 GB 888813527 A GB888813527 A GB 888813527A GB 8813527 A GB8813527 A GB 8813527A GB 8813527 D0 GB8813527 D0 GB 8813527D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- bispecific antibodies
- bispecific
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888813527A GB8813527D0 (en) | 1988-06-08 | 1988-06-08 | Bispecific antibodies |
PCT/GB1989/000641 WO1989011863A1 (en) | 1988-06-08 | 1989-06-08 | Bispecific antibodies |
AU37520/89A AU3752089A (en) | 1988-06-08 | 1989-06-08 | Bispecific antibodies |
EP89906797A EP0422043A1 (en) | 1988-06-08 | 1989-06-08 | Bispecific antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888813527A GB8813527D0 (en) | 1988-06-08 | 1988-06-08 | Bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
GB8813527D0 true GB8813527D0 (en) | 1988-07-13 |
Family
ID=10638262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB888813527A Pending GB8813527D0 (en) | 1988-06-08 | 1988-06-08 | Bispecific antibodies |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0422043A1 (en) |
AU (1) | AU3752089A (en) |
GB (1) | GB8813527D0 (en) |
WO (1) | WO1989011863A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354554A (en) * | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
WO1991012023A2 (en) | 1990-02-16 | 1991-08-22 | Boston Biomedical Research Institute | Hybrid reagents capable of selectively releasing molecules into cells |
IL97459A0 (en) * | 1990-03-09 | 1992-06-21 | Hybritech Inc | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
US5273743A (en) * | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
ZA914625B (en) * | 1990-06-22 | 1993-02-24 | Lilly Co Eli | In vivo targeting with bifunctional antibodies |
US6685930B1 (en) * | 1991-03-27 | 2004-02-03 | Tanox, Inc. | Methods and substances for recruiting therapeutic agents to solid tumors |
US6497881B1 (en) * | 1995-11-30 | 2002-12-24 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
-
1988
- 1988-06-08 GB GB888813527A patent/GB8813527D0/en active Pending
-
1989
- 1989-06-08 WO PCT/GB1989/000641 patent/WO1989011863A1/en not_active Application Discontinuation
- 1989-06-08 EP EP89906797A patent/EP0422043A1/en not_active Withdrawn
- 1989-06-08 AU AU37520/89A patent/AU3752089A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU3752089A (en) | 1990-01-05 |
WO1989011863A1 (en) | 1989-12-14 |
EP0422043A1 (en) | 1991-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB8905669D0 (en) | Modified antibodies | |
GB8608068D0 (en) | Monoclonal antibodies | |
IL90017A0 (en) | Monoclonal antibodies | |
ZA898777B (en) | Monoclonal antibodies | |
GB8621910D0 (en) | Monoclonal antibodies | |
ZA898499B (en) | Anti-fucosylcermiade monoclonal antibody | |
GB8813527D0 (en) | Bispecific antibodies | |
GB8726230D0 (en) | Antibodies | |
GB8616174D0 (en) | Monoclonal antibodies | |
ZA89258B (en) | Monoclonal antibodies | |
GB8820036D0 (en) | Monoclonal antibodies | |
GB8927389D0 (en) | Monoclonal antibodies | |
GB8812137D0 (en) | Antibodies | |
GB8610202D0 (en) | Monoclonal antibodies | |
GB8610203D0 (en) | Monoclonal antibodies | |
EP0423333A4 (en) | Anti-endoserine antibody | |
EP0336441A3 (en) | Anti-cpbii monoclonal antibody | |
GB9318912D0 (en) | Humanised antibodies | |
GB8812962D0 (en) | Monoclonal antibodies | |
GB8812963D0 (en) | Monoclonal antibodies | |
GB8820035D0 (en) | Monoclonal antibodies | |
ZA892882B (en) | Monoclonal antibodies | |
GB8812353D0 (en) | Antibodies | |
ZA891069B (en) | Antibodies | |
GB8718164D0 (en) | Monoclonal antibodies |